GSK has agreed to pay $20 M upfront plus up to another $630 M in milestones payments to gain access to Epizyme's gene-regulating enzyme technology. The enzymes, called histone methyltransferases (HMTs), have application to diseases like cancer, inflammation, metabolic diseases, and neurodegenerative diseases. Epigenetic enzyme determine whether genes are turned on or turned off.
Epizyme's CEO and president, Robert Gould, said the company's goal is to develop personalized medicine therapeutics based on our understanding of the role played by HMTs in human disease. See Xconomy and Fierce Biotech.
Posted by Bruce Lehr Jan 13th 2011.